CYBN.NE
Cybin Inc.
1W: +4.5%
1M: -34.3%
3M: -17.1%
YTD: -21.1%
1Y: -48.1%
3Y: -68.1%
5Y: -90.5%
C$6.28 ($4.53)
-0.24 (-3.68%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market CapC$152.0M ($109.8M)
52W Range6.2-15.27
Volume3,416
Avg Volume19,421
Beta0.79
Dividend—
Analyst Ratings
Company Info
100 King Street West
Toronto, ON M5X 1C9
CA
Toronto, ON M5X 1C9
CA
908 764 8385
About Cybin Inc.
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
Latest News
No recent news
Recent Insider Trades
No insider trades found